BOSTON, March 13, 2024 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced today that Novartis has exercised its option to acquire all of the outstanding capital stock of IFM Due, a subsidiary company of IFM.

波士顿，2024年3月13日/PRNewswire/--IFM Therapeutics（IFM），一家专注于开发调节先天免疫系统新靶点的疗法的私营生物制药公司，今天宣布诺华已行使其期权，收购IFM Due（IFM的子公司）的所有流通股本。

Launched in February 2019, with a focus on developing small molecules that inhibit the cGAS-STING pathway, the company entered into an option and collaboration agreement with Novartis in September, 2019 whereby Novartis made fixed payments sufficient to fully finance IFM Due's research and development costs for the cGAS-STING program in exchange for the option to acquire the IFM Due subsidiary (link).

该公司于2019年2月成立，专注于开发抑制cGAS-STING途径的小分子，并于9月与诺华签订了选择和合作协议，2019年，诺华支付了足够的固定款项，以全额资助IFM Due在cGAS STING计划中的研发成本，以换取收购IFM Due子公司（link）的选择权。

Under the terms of the option exercise, IFM received $90 million in upfront payment and will be eligible for up to $745 million in milestone payments, adding up to $835 million in total consideration..

根据期权行使条款，IFM收到了9000万美元的预付款，将有资格获得高达7.45亿美元的里程碑付款，总计8.35亿美元。

The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, which have the potential to treat an array of serious inflammation-driven diseases characterized by excessive interferon and other pro-inflammatory cytokine signaling.

此次收购为诺华提供了IFM Due STING拮抗剂组合的全部权利，这些药物有可能治疗一系列严重的炎症驱动疾病，其特征是干扰素和其他促炎细胞因子信号过度。

'The acquisition of IFM Due represents the culmination of a highly productive, four-year preclinical collaboration between Novartis and IFM to develop novel small-molecule STING inhibitors with the potential to treat a spectrum of inflammatory diseases,' said Richard Siegel, global head of immunology research at Novartis.

诺华公司免疫学研究全球负责人理查德·西格尔（RichardSiegel）说：“收购IFM-Due代表了诺华公司与IFM公司之间高效、为期四年的临床前合作的高潮，该合作旨在开发新型小分子STING抑制剂，具有治疗一系列炎性疾病的潜力。”

'We are excited to advance IFM Due's STING program and leverage our deep expertise in inflammation science to bring forward transformative medicines that address major unmet patient needs.' .

“我们很高兴推进IFM Due的STING计划，并利用我们在炎症科学方面的深厚专业知识，推出针对未满足患者主要需求的变革性药物。”

'We have been steadfast in our belief that selectively targeting STING to block the cGAS-STING pathway has the potential to deliver a powerful therapeutic option for patients with serious chronic illnesses,' said H. Martin Seidel, chief executive officer of IFM. 'Novartis has been an outstanding collaborator, and the program couldn't be in better hands.

IFM首席执行官H.Martin Seidel说：“我们一直坚信，选择性靶向STING阻断cGAS-STING途径有可能为严重慢性病患者提供强大的治疗选择。诺华一直是一个出色的合作者，这个项目再好不过了。”

Today, as IFM Therapeutics marks the third major acquisition by a global pharmaceutical company, we cannot be more proud of our team's accomplishments and look forward to seeing our vision of precisely targeting the innate immune system to address a variety of serious inflammation-driven diseases become a reality for patients in need.'.

今天，随着IFM Therapeutics标志着全球制药公司的第三次重大收购，我们对我们团队的成就感到无比骄傲，并期待着看到我们的愿景，即精确定位先天免疫系统，以解决各种严重的炎症驱动疾病，成为有需要的患者的现实。”

The cGAS-STING (cyclic GMP-AMP Synthase, Stimulator of Interferon Genes) pathway functions within the innate immune system to sense cytosolic DNA, which is a signal of cellular danger, and then triggers a STING-dependent inflammatory response. Inappropriate pathway activation, which leads to excessive interferon/cytokine signaling, can result from mutations that activate the pathway or other drivers of aberrant pathway activation, such as mitochondrial dysfunction.

cGAS-STING（环状GMP-AMP合酶，干扰素基因刺激物）途径在先天免疫系统内起作用，以感知细胞溶质DNA，这是细胞危险的信号，然后触发STING依赖性炎症反应。不适当的途径激活会导致过量的干扰素/细胞因子信号传导，这可能是由激活该途径的突变或异常途径激活的其他驱动因素（例如线粒体功能障碍）引起的。

Such pathway dysregulation is believed to underlie a variety of serious inflammation-driven diseases..

这种途径失调被认为是各种严重炎症驱动疾病的基础。

About IFM Due

关于IFM到期

IFM Due (pronounced du-eh), a subsidiary of IFM Therapeutics, is a biopharmaceutical company developing small-molecule, orally available drug candidates targeting aberrant inflammatory responses of the innate immune system triggered by the cGAS-STING pathway, which is believed to underlie a variety of serious diseases..

IFM-Due（发音为du eh）是IFM Therapeutics的子公司，是一家生物制药公司，开发小分子口服候选药物，靶向由cGAS-STING途径触发的先天免疫系统异常炎症反应，据信这是多种严重疾病的基础。

About IFM Therapeutics

关于IFM Therapeutics

IFM Therapeutics (IFM) is a privately held biopharmaceutical company based in Boston, Massachusetts and financed by Atlas Venture, Abingworth, and Novartis. The company, founded in 2015 by Atlas Venture, Gary Glick and an international group of preeminent scientists and physicians, has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, auto-immunity, and inflammatory disorders.

IFM Therapeutics（IFM）是一家总部位于马萨诸塞州波士顿的私营生物制药公司，由Atlas Venture，Abingworth和Novartis资助。该公司于2015年由Atlas Venture、Gary Glick和一个由杰出科学家和医生组成的国际小组成立，该公司发现并开发了调节先天免疫系统新靶点的小分子，作为癌症、自身免疫和炎症性疾病的下一代疗法。

IFM places each program in its own dedicated, independently financed, R&D-focused subsidiary company, which is supported by the common infrastructure, management team and resources of the IFM enterprise.  For more information on IFM and its model, please visit https://www.ifmthera.com..

IFM将每个项目放在自己专门的、独立融资的、以研发为重点的子公司中，该子公司由IFM企业的公共基础设施、管理团队和资源支持。有关IFM及其模型的更多信息，请访问https://www.ifmthera.com.